Thursday, Dec. 14, 2017 - Hepatitis C and Renal Transplantation in the Era of New Antiviral Agents

Thursday, December 14, 2017 - 10am EST (4pm Madrid) - José Maria Morales

Please enter your information below to sign up for the webinar.
First Name (*) Invalid Input
Last Name (*) Invalid Input
Email (*) Invalid Input

TTS-TID Webinar Thursday, December 14, 2017

TID 2016 webinars

TTS-TID Webinar
Hepatitis C and Renal Transplantation in the Era of New Antiviral Agents
Thursday, December 14, 2017 - 10am EST (4pm Madrid)


Speaker:  

Professor José Maria Morales, MD, PhD
Professor of Medicine, Past-Medical Director Renal Transplant Program
Hospital 12 de Octubre
Madrid, Spain

  Professor José Maria Morales, MD, PhD Professor of Medicine, Past-Medical Director Renal Transplant Program Hospital 12 de Octubre Madrid, Spain

Moderator:  

Dr. Edson Abdala, MD, PhD
Associate Professor, Infectious Diseases
University of São Paulo Medical School
Presidente, Immunocompromised Host Infection Committee
Clinics Hospital, University of São Paulo Medical School

  Dr. Edson Abdala, MD, PhD Associate Professor, Infectious Diseases University of São Paulo Medical School Presidente, Immunocompromised Host Infection Committee Clinics Hospital, University of São Paulo Medical School

Biography:

Jose M Morales is Professor of Medicine and currently Consultant Investigator in the Research Institute of Hospital 12 de Octubre of Madrid, Spain. He is Past-President of the Madrid Transplantation Society and Past- Chief of Renal Transplant Program in Hospital 12 de Octubre. His main clinical and investigational activity has been  focused on renal transplantation, especially Hepatitis C and immunosuppression, publishing more than 250 peer-review papers (H-index 38). He is a member of the experts who developed the KDIGO guidelines for Hepatitis C in chronic kidney disease in 2008 and 2017. He is the Vice-Chair of the 27th Congress of the Transplantation Society that will be held in Madrid 30 June-5 July, 2018.

Overview:

Hepatitis C infection after renal transplantation can induce severe liver disease and lower patient and graft survival in HCV-infected compared with HCV negative patients.  The successful use of new direct-acting antivirals for hepatitis C is changing the landscape of this complication in renal transplant patients. Therefore, if these drugs become available for all patients and their use is not restricted by the cost, probably Hepatitis C will not be a problem and will show excellent results after renal transplantation worldwide.


Thursday, December 14, 2017 - 10am EST (4pm Madrid)

AccraThu 15:00CasablancaThu 15:00KolkataThu 20:30ReykjavikThu 15:00
Addis AbabaThu 18:00ChicagoThu 09:00Kuala LumpurThu 23:00Rio de Janeiro *Thu 13:00
Adelaide *Fri 01:30CopenhagenThu 16:00Kuwait CityThu 18:00RiyadhThu 18:00
AlgiersThu 16:00DallasThu 09:00KyivThu 17:00RomeThu 16:00
AlmatyThu 21:00Dar es SalaamThu 18:00La PazThu 11:00Salt Lake CityThu 08:00
AmmanThu 17:00DarwinFri 00:30LagosThu 16:00San FranciscoThu 07:00
AmsterdamThu 16:00DenverThu 08:00LahoreThu 20:00San JuanThu 11:00
AnadyrFri 03:00DetroitThu 10:00Las VegasThu 07:00San SalvadorThu 09:00
AnchorageThu 06:00DhakaThu 21:00LimaThu 10:00Santiago *Thu 12:00
AnkaraThu 18:00DohaThu 18:00LisbonThu 15:00Santo DomingoThu 11:00
AntananarivoThu 18:00DubaiThu 19:00LondonThu 15:00São Paulo *Thu 13:00
Asuncion *Thu 12:00DublinThu 15:00Los AngelesThu 07:00SeattleThu 07:00
AthensThu 17:00EdmontonThu 08:00MadridThu 16:00SeoulFri 00:00
AtlantaThu 10:00FrankfurtThu 16:00ManaguaThu 09:00ShanghaiThu 23:00
Auckland *Fri 04:00Guatemala CityThu 09:00ManilaThu 23:00SingaporeThu 23:00
BaghdadThu 18:00HalifaxThu 11:00Melbourne *Fri 02:00SofiaThu 17:00
BangaloreThu 20:30HanoiThu 22:00Mexico CityThu 09:00St. John'sThu 11:30
BangkokThu 22:00HarareThu 17:00MiamiThu 10:00StockholmThu 16:00
BarcelonaThu 16:00HavanaThu 10:00MinneapolisThu 09:00Suva *Fri 04:00
BeijingThu 23:00HelsinkiThu 17:00MinskThu 18:00Sydney *Fri 02:00
BeirutThu 17:00Hong KongThu 23:00MontevideoThu 12:00TaipeiThu 23:00
BelgradeThu 16:00HonoluluThu 05:00MontréalThu 10:00TallinnThu 17:00
BerlinThu 16:00HoustonThu 09:00MoscowThu 18:00TashkentThu 20:00
BogotaThu 10:00IndianapolisThu 10:00MumbaiThu 20:30TegucigalpaThu 09:00
BostonThu 10:00IslamabadThu 20:00NairobiThu 18:00TehranThu 18:30
Brasilia *Thu 13:00IstanbulThu 18:00NassauThu 10:00TokyoFri 00:00
BrisbaneFri 01:00JakartaThu 22:00New DelhiThu 20:30TorontoThu 10:00
BrusselsThu 16:00JerusalemThu 17:00New OrleansThu 09:00VancouverThu 07:00
BucharestThu 17:00JohannesburgThu 17:00New YorkThu 10:00ViennaThu 16:00
BudapestThu 16:00KabulThu 19:30OsloThu 16:00WarsawThu 16:00
Buenos AiresThu 12:00KarachiThu 20:00OttawaThu 10:00Washington DCThu 10:00
CairoThu 17:00KathmanduThu 20:45ParisThu 16:00WinnipegThu 09:00
CalgaryThu 08:00KhartoumThu 17:00PerthThu 23:00YangonThu 21:30
Canberra *Fri 02:00KingstonThu 10:00PhiladelphiaThu 10:00ZagrebThu 16:00
Cape TownThu 17:00KinshasaThu 16:00PhoenixThu 08:00ZürichThu 16:00
CaracasThu 11:00KiritimatiFri 05:00PragueThu 16:00

* = Adjusted for DST or summer time (11 places).
Thu = Thursday, December 14, 2017 (131 places).
Fri = Friday, December 15, 2017 (12 places).
UTC (GMT/Zulu)-time: Thursday, December 14, 2017 at 15:00:00
UTC is Coordinated Universal Time, GMT is Greenwich Mean Time.

Our Corporate Sponsors

TTS gratefully acknowledges the Corporate Partners whose generous support makes the work of the Society possible:

  • astellas
  • roche
  • sanofi